Drug intelligence / Profile preview

(5-(pyridin-3-yl)furan-2-yl)methanamine

Development stage: Unknown
Modality: Small Molecules

Overview

(5-(pyridin-3-yl)furan-2-yl)methanamine is a synthetic small molecule belonging to the aralkylamines class. It features a furan ring substituted at the 2-position with an aminomethyl group and at the 5-position with a pyridin‑3‑yl group. The compound has been studied as an experimental inhibitor of cytochrome P450 2D6 (CYP2D6), an enzyme involved in drug metabolism. There are no approved indications or clinical uses for this compound; it is not marketed and remains in preclinical or early research stages[1][4][7].

Other names: (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE[5-(pyridin-3-yl)furan-2-yl]methanamine(5-pyridin-3-ylfuran-2-yl)methanamine1-(5-pyridin-3-ylfuran-2-yl)methanamineCHEBI:41804

Targets

CYP2D6 (Cytochrome P450 2D6)

Beyond the preview

Go deeper on (5-(pyridin-3-yl)furan-2-yl)methanamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on (5-(pyridin-3-yl)furan-2-yl)methanamine.

Explore the full profile